{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:01:34Z","timestamp":1790845294794,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT94252510612"],"award-info":[{"award-number":["HT94252510612"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA014520"],"award-info":[{"award-number":["P30CA014520"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04489-7","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:46:42Z","timestamp":1783424802000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CXCL13-CXCR5 signaling in CD8+ T cell recruitment and lymphoid immune organization in clear cell renal cell carcinoma"],"prefix":"10.1007","volume":"75","author":[{"given":"Daniel D.","family":"Shapiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kye D.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlos","family":"Msaouel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Esbona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshi","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paz","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Roadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everlyne","family":"Nkadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Beebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena C.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Capitini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin Jason","family":"Abel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"4489_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030478","author":"DD Shapiro","year":"2024","unstructured":"Shapiro DD, Lozar T, Cheng L, Xie E, Laklouk I, Lee MH et al (2024) Non-metastatic clear cell renal cell carcinoma immune cell infiltration heterogeneity and prognostic ability in patients following surgery. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16030478","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4489_CR2","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13059-016-1092-z","volume":"17","author":"Y \u015eenbabao\u011flu","year":"2016","unstructured":"\u015eenbabao\u011flu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N (2016) Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol 17(1):231. https:\/\/doi.org\/10.1186\/s13059-016-1092-z","journal-title":"Genome Biol"},{"issue":"6","key":"4489_CR3","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1158\/0008-5472.can-16-2490PMID-28126714","volume":"77","author":"FS Varn","year":"2017","unstructured":"Varn FS, Wang Y, Mullins DW, Fiering S, Cheng C (2017) Systematic pan-cancer analysis reveals immune cell interactions in the tumor microenvironment. Cancer Res 77(6):1271\u20131282. https:\/\/doi.org\/10.1158\/0008-5472.can-16-2490PMID-28126714","journal-title":"Cancer Res"},{"key":"4489_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092500","author":"DD Shapiro","year":"2023","unstructured":"Shapiro DD, Dolan B, Laklouk IA, Rassi S, Lozar T, Emamekhoo H et al (2023) Understanding the tumor immune microenvironment in renal cell carcinoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15092500","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4489_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.eururo.2021.02.025","volume":"80","author":"AF Correa","year":"2021","unstructured":"Correa AF, Jegede OA, Haas NB, Flaherty KT, Pins MR, Adeniran A et al (2021) Predicting disease recurrence, early progression, and overall survival following surgical resection for high-risk localized and locally advanced renal cell carcinoma. Eur Urol 80(1):20\u201331. https:\/\/doi.org\/10.1016\/j.eururo.2021.02.025","journal-title":"Eur Urol"},{"issue":"13","key":"4489_CR6","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1158\/1078-0432.ccr-14-2926PMID-25688160","volume":"21","author":"NA Giraldo","year":"2015","unstructured":"Giraldo NA, Becht E, Pag\u00e8s F, Skliris G, Verkarre V, Vano Y et al (2015) Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin Cancer Res 21(13):3031\u20133040. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-2926PMID-25688160","journal-title":"Clin Cancer Res"},{"issue":"7787","key":"4489_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","volume":"576","author":"CS Jansen","year":"2019","unstructured":"Jansen CS, Prokhnevska N, Master VA, Sanda MG, Carlisle JW, Bilen MA et al (2019) An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 576(7787):465\u2013470. https:\/\/doi.org\/10.1038\/s41586-019-1836-5","journal-title":"Nature"},{"issue":"5","key":"4489_CR8","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ccell.2021.02.013PMID-33711273","volume":"39","author":"DA Braun","year":"2021","unstructured":"Braun DA, Street K, Burke KP, Cookmeyer DL, Denize T, Pedersen CB et al (2021) Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell 39(5):632\u201348.e8. https:\/\/doi.org\/10.1016\/j.ccell.2021.02.013PMID-33711273","journal-title":"Cancer Cell"},{"key":"4489_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.011","author":"I Mellman","year":"2023","unstructured":"Mellman I, Chen DS, Powles T, Turley SJ (2023) The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. https:\/\/doi.org\/10.1016\/j.immuni.2023.09.011","journal-title":"Immunity"},{"issue":"1","key":"4489_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012PMID-23890059","volume":"39","author":"S Chen Daniel","year":"2013","unstructured":"Chen Daniel S, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1):1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012PMID-23890059","journal-title":"Immunity"},{"key":"4489_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.12.002","author":"N Prokhnevska","year":"2022","unstructured":"Prokhnevska N, Cardenas MA, Valanparambil RM, Sobierajska E, Barwick BG, Jansen C et al (2022) CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity. https:\/\/doi.org\/10.1016\/j.immuni.2022.12.002","journal-title":"Immunity"},{"issue":"7620","key":"4489_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC et al (2016) Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537(7620):417\u2013421. https:\/\/doi.org\/10.1038\/nature19330","journal-title":"Nature"},{"issue":"3","key":"4489_CR13","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, Sen DR, Abosy RA, Bi K, Virkud YV, LaFleur MW et al (2019) Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol 20(3):326\u2013336. https:\/\/doi.org\/10.1038\/s41590-019-0312-6","journal-title":"Nat Immunol"},{"issue":"1","key":"4489_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui I, Schaeuble K, Chennupati V, Marraco SAF, Calderon-Copete S, Ferreira DP et al (2019) Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50(1):195-211.e10. https:\/\/doi.org\/10.1016\/j.immuni.2018.12.021","journal-title":"Immunity"},{"issue":"11","key":"4489_CR15","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1038\/s41375-019-0464-2","volume":"33","author":"F Chu","year":"2019","unstructured":"Chu F, Li HS, Liu X, Cao J, Ma W, Ma Y et al (2019) CXCR5(+)CD8(+) T cells are a distinct functional subset with an antitumor activity. Leukemia 33(11):2640\u20132653. https:\/\/doi.org\/10.1038\/s41375-019-0464-2","journal-title":"Leukemia"},{"issue":"12","key":"4489_CR16","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1002\/eji.200636746","volume":"37","author":"MF Quigley","year":"2007","unstructured":"Quigley MF, Gonzalez VD, Granath A, Andersson J, Sandberg JK (2007) CXCR5+ CCR7- CD8 T cells are early effector memory cells that infiltrate tonsil B cell follicles. Eur J Immunol 37(12):3352\u20133362. https:\/\/doi.org\/10.1002\/eji.200636746","journal-title":"Eur J Immunol"},{"key":"4489_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay6863","author":"W Held","year":"2019","unstructured":"Held W, Siddiqui I, Schaeuble K, Speiser DE (2019) Intratumoral CD8(+) T cells with stem cell-like properties: implications for cancer immunotherapy. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aay6863","journal-title":"Sci Transl Med"},{"issue":"12","key":"4489_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/life11121282","volume":"11","author":"S-H Gao","year":"2021","unstructured":"Gao S-H, Liu S-Z, Wang G-Z, Zhou G-B (2021) CXCL13 in cancer and other diseases: biological functions, clinical significance, and therapeutic opportunities. Life (Basel) 11(12):1282. https:\/\/doi.org\/10.3390\/life11121282","journal-title":"Life (Basel)"},{"issue":"1","key":"4489_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41568-023-00635-w","volume":"24","author":"TR Mempel","year":"2024","unstructured":"Mempel TR, Lill JK, Altenburger LM (2024) How chemokines organize the tumour microenvironment. Nat Rev Cancer 24(1):28\u201350. https:\/\/doi.org\/10.1038\/s41568-023-00635-w","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"4489_CR20","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","volume":"54","author":"AJ Ozga","year":"2021","unstructured":"Ozga AJ, Chow MT, Luster AD (2021) Chemokines and the immune response to cancer. Immunity 54(5):859\u2013874. https:\/\/doi.org\/10.1016\/j.immuni.2021.01.012","journal-title":"Immunity"},{"key":"4489_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.lfs.2019.04.053","volume":"227","author":"M Hussain","year":"2019","unstructured":"Hussain M, Adah D, Tariq M, Lu Y, Zhang J, Liu J (2019) CXCL13\/CXCR5 signaling axis in cancer. Life Sci 227:175\u2013186. https:\/\/doi.org\/10.1016\/j.lfs.2019.04.053","journal-title":"Life Sci"},{"issue":"2","key":"4489_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10549-013-2811-8","volume":"143","author":"S Biswas","year":"2014","unstructured":"Biswas S, Sengupta S, Chowdhury SR, Jana S, Mandal G, Mandal PK et al (2014) CXCL13\u2013CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis. Breast Cancer Res Treat 143(2):265\u2013276. https:\/\/doi.org\/10.1007\/s10549-013-2811-8","journal-title":"Breast Cancer Res Treat"},{"key":"4489_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejca.2021.01.036","volume":"148","author":"CS Groeneveld","year":"2021","unstructured":"Groeneveld CS, Fontugne J, Cabel L, Bernard-Pierrot I, Radvanyi F, Allory Y et al (2021) Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. Eur J Cancer 148:181\u2013189. https:\/\/doi.org\/10.1016\/j.ejca.2021.01.036","journal-title":"Eur J Cancer"},{"key":"4489_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc4220","author":"S Goswami","year":"2020","unstructured":"Goswami S, Chen Y, Anandhan S, Szabo PM, Basu S, Blando JM et al (2020) ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.abc4220","journal-title":"Sci Transl Med"},{"key":"4489_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.11.043","author":"JA Karam","year":"2011","unstructured":"Karam JA, Zhang XY, Tamboli P, Margulis V, Wang H, Abel EJ et al (2011) Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2010.11.043","journal-title":"Eur Urol"},{"key":"4489_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103634","author":"KM Lugo-Cintr\u00f3n","year":"2021","unstructured":"Lugo-Cintr\u00f3n KM, Ayuso JM, Humayun M, Gong MM, Kerr SC, Ponik SM et al (2021) Primary head and neck tumour-derived fibroblasts promote lymphangiogenesis in a lymphatic organotypic co-culture model. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103634","journal-title":"EBioMedicine"},{"key":"4489_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201500608","author":"JA Jim\u00e9nez-Torres","year":"2016","unstructured":"Jim\u00e9nez-Torres JA, Peery SL, Sung KE, Beebe DJ (2016) LumeNEXT: a practical method to pattern luminal structures in ECM gels. Adv Healthc Mater. https:\/\/doi.org\/10.1002\/adhm.201500608","journal-title":"Adv Healthc Mater"},{"key":"4489_CR28","doi-asserted-by":"publisher","unstructured":"Jim\u00e9nez-Torres JA, Beebe DJ, Sung KE. (2016) A microfluidic method to mimic luminal structures in the tumor microenvironment. Methods in molecular biology (Clifton, NJ). 1458. https:\/\/doi.org\/10.1007\/978-1-4939-3801-8_5","DOI":"10.1007\/978-1-4939-3801-8_5"},{"key":"4489_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2016.07.005","author":"TM Bauman","year":"2016","unstructured":"Bauman TM, Huang W, Lee MH, Abel EJ (2016) Neovascularity as a prognostic marker in renal cell carcinoma. Hum Pathol. https:\/\/doi.org\/10.1016\/j.humpath.2016.07.005","journal-title":"Hum Pathol"},{"key":"4489_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.11.001","author":"R Li","year":"2022","unstructured":"Li R, Ferdinand JR, Loudon KW, Bowyer GS, Laidlaw S, Muyas F et al (2022) Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer. Cancer Cell. https:\/\/doi.org\/10.1016\/j.ccell.2022.11.001","journal-title":"Cancer Cell"},{"issue":"5","key":"4489_CR31","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ccell.2021.03.007PMID-33861994","volume":"39","author":"C Krishna","year":"2021","unstructured":"Krishna C, DiNatale RG, Kuo F, Srivastava RM, Vuong L, Chowell D et al (2021) Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. Cancer Cell 39(5):662\u201377.e6. https:\/\/doi.org\/10.1016\/j.ccell.2021.03.007PMID-33861994","journal-title":"Cancer Cell"},{"issue":"7745","key":"4489_CR32","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41586-019-0969-x","volume":"566","author":"J Cao","year":"2019","unstructured":"Cao J, Spielmann M, Qiu X, Huang X, Ibrahim DM, Hill AJ et al (2019) The single-cell transcriptional landscape of mammalian organogenesis. Nature 566(7745):496\u2013502. https:\/\/doi.org\/10.1038\/s41586-019-0969-x","journal-title":"Nature"},{"issue":"16","key":"4489_CR33","doi-asserted-by":"publisher","first-page":"1551259","DOI":"10.3389\/fimmu.2025.1551259","volume":"8","author":"S Xu","year":"2025","unstructured":"Xu S, Li D, Ning T, Lu Y, Sun Y, Bai H, Qiao L, Deng T, Liu Y (2025) High expression of CXCL13 predicts a favorable response to immunotherapy by upregulating CXCR5+ CD8+ T-cell infiltration in gastric cancer. Front Immunol 8(16):1551259. https:\/\/doi.org\/10.3389\/fimmu.2025.1551259","journal-title":"Front Immunol"},{"issue":"3","key":"4489_CR34","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ccell.2022.01.002","volume":"40","author":"A Asrir","year":"2022","unstructured":"Asrir A, Tardiveau C, Coudert J, Laffont R, Blanchard L, Bellard E et al (2022) Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell 40(3):318\u201334.e9. https:\/\/doi.org\/10.1016\/j.ccell.2022.01.002","journal-title":"Cancer Cell"},{"key":"4489_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119225","author":"MM Gong","year":"2019","unstructured":"Gong MM, Lugo-Cintron KM, White BR, Kerr SC, Harari PM, Beebe DJ (2019) Human organotypic lymphatic vessel model elucidates microenvironment-dependent signaling and barrier function. Biomaterials. https:\/\/doi.org\/10.1016\/j.biomaterials.2019.119225","journal-title":"Biomaterials"},{"issue":"12","key":"4489_CR36","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.4049\/jimmunol.2100082","volume":"206","author":"SM Elzein","year":"2021","unstructured":"Elzein SM, Zimmerer JM, Han JL, Ringwald BA, Bumgardner GL (2021) CXCR5(+)CD8(+) T cells: a review of their antibody regulatory functions and clinical correlations. J Immunol 206(12):2775\u20132783. https:\/\/doi.org\/10.4049\/jimmunol.2100082","journal-title":"J Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04489-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04489-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04489-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:42:10Z","timestamp":1790844130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04489-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4489"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04489-7","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"3 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Pavlos Msaouel has received honoraria for service on a Scientific Advisory Board for Mirati Therapeutics, Bristol Myers Squibb, and Exelixis; consulting for Axiom Healthcare Strategies; non-branded educational programs supported by DAVA Oncology, Exelixis and Pfizer; and research funding for clinical trials from Regeneron Pharmaceuticals, Summit Therapeutics, Merck, Takeda, Bristol Myers Squibb, Mirati Therapeutics, Gateway for Cancer Research, and the University of Texas MD Anderson Cancer Center. David J. Beebe holds equity in Bellbrook Labs LLC, Salus Discovery LLC, Lynx Biosciences Inc., Stacks to the Future LLC, Flambeau Diagnostics LLC, Navitro Biosciences LLC, Eolas Diagnostics, Inc., and Onexio Biosystems LLC. Christian M. Capitini has received honoraria from Bayer and Novartis, and equity interest from Elephas, for advisory board memberships. These companies had no input in the study design, analysis, manuscript preparation or decision to submit for publication. The remaining authors have no conflict of interest to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval for human subject work was granted by the Ethics Committee of the University of Wisconsin (#2024\u20130997). Approval for investigations involving mice was granted by the University of Wisconsin-Madison Institutional Animal Care and Use Committee (#M006825-A02).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For all research involving human subjects, freely-given, informed consent to participate in this study was obtained from all participants. All participants were\u2009\u2265\u200918\u00a0years of age.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"241"}}